Skip to main content
. 2022 Mar 31;11(3):937–951. doi: 10.1007/s40121-022-00609-9

Table 1.

Currently available meningococcal vaccines

Name Meningococcal serogroup Type US licensed age range
Menactra (MenACWY-D) [10] A, C, W, Y Polysaccharides conjugated to diphtheria toxoid

9 months −

55 years
Menveo (MenACWY-CRM) [11] A, C, W, Y Polysaccharides conjugated to CRM197, a (nontoxic) mutant diphtheria toxin

2 months–

55 years
MenQuadfi (MenACYW-TT) [12] A, C, W, Y Polysaccharides conjugated to tetanus toxoid  ≥ 2 years
Nimenrix (MenACWY-TT) [13] A, C, W, Y Polysaccharides conjugated to tetanus toxoid  ≥ 6 weeksa
Bexsero (MenB-4C) [50] B Recombinant-derived outer membrane proteins NadA, NHBA, fHbp (subfamily B), plus PorA-containing outer membrane vesicles 10 − 25 years
Trumenba (MenB-FHbp) [51] B Recombinant-derived lipidated fHbp (subfamily A and B) 10 − 25 years

fHbp factor H binding protein, NadA neisserial adhesin A, NHBA neisserial heparin binding antigen

aNot currently licensed in the United States